Bristol Myers Squibb reports positive phase 4 data on Cobenfy for schizophrenia patients

The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks

Kenvue unleashes science-driven skincare offensive at American Academy of Dermatology meet

The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection

ENHERTU approved in China as first HER2-targeted ADC for early breast cancer

The decision is based on the phase 3 DESTINY-Breast11 trial

Allergan Aesthetics showcases breakthroughs at AAD 2026

Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments

Corona Remedies acquires antiseptic brand Wokadine from Dr Reddy’s to enter Iodine market

This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility

Sun Pharma to spotlight 14 dermatology studies at 2026 AAD annual meeting

The presentations underscore the company’s deep expertise in dermatology and immunology

AbbVie stakes claim to redefine skin disease treatment at Global Dermatology Summit

Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims

Eli Lilly drug shows 4-year relief for eczema patients, study finds

The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection

AstraZeneca’s breakthrough COPD drug Tozorakimab slashes flare-ups in landmark Phase III trials

High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo

New diabetes drug UBT251 shows strong phase 2 results in China